In a single infusion, YESCARTA can help you achieve complete and lasting remission from follicular lymphoma

YESCARTA was studied in adults with follicular lymphoma who had experienced 2 or more treatment failures. Patients were followed for a median of about 18 months after receiving YESCARTA to gather these results:

60% of Patients Achieved
Complete Remission,
seeing a disappearance of all signs of cancer.
This does not always mean the cancer has been cured.

31% of Patients Achieved
Partial Remission,
experiencing a decrease in the amount of cancer within the body.

Most of the patients who achieved remission are still in remission a year and a half after treatment.

Efficacy chart

Remission is possible in as little as 1 month after treatment

In the YESCARTA clinical study, half of patients with follicular lymphoma achieved remission in as little as 1 month after treatment (range 0.8–3.1 months).

YESCARTA is a single infusion that puts millions of cancer-fighting CAR T cells into your body


It starts with your own T cells

Your immune system has different types of white blood cells, all working together to keep you healthy. One type of white blood cell, called the T cell, has the very important job of finding and destroying things that can harm your body, like infection or cancer. In some cases, however, your T cells aren't able to recognize cancer cells.

T cells T cells T cells
Purple T cell icon T cells
Purple T cell icon T cells
Purple T cell icon T cells

YESCARTA helps your T cells do the job they were meant to do

The YESCARTA treatment process takes your own T cells and modifies them with a special connector, called a chimeric antigen receptor, or CAR. With just one YESCARTA infusion, millions of CAR T cells are put into your body with a better ability to recognize and destroy cancer cells.